menu search

GLYC / GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer Edwin Rock - Chief Medical Officer Brian Hahn - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - TD Cowen Operator Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode. Read More
Posted: Nov 3 2023, 12:24
Author Name: Seeking Alpha
Views: 022847

GLYC News  

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 3, 2023

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General more_horizontal

GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy

By Seeking Alpha
May 30, 2023

GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy

GlycoMimetics' Phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until early 2024, with the FDA seeking more information more_horizontal

GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology

By Seeking Alpha
May 10, 2023

GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology

Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood cancers such as AML, MM, a more_horizontal

GlycoMimetics: Stock Price Drop Brings Great Speculative Trade Opportunity

By Seeking Alpha
March 8, 2023

GlycoMimetics: Stock Price Drop Brings Great Speculative Trade Opportunity

Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the tr more_horizontal

GLYC Stock: 62.47% Plummet Explanation

By Pulse2
February 16, 2023

GLYC Stock: 62.47% Plummet Explanation

The stock price of GlycoMimetics Inc (NASDAQ: GLYC) dropped by 62.47% in the most recent trading session. This is why. more_horizontal

GlycoMimetics: A Cancer-Cure Lottery Ticket Grabbing My Attention

By Seeking Alpha
January 3, 2023

GlycoMimetics: A Cancer-Cure Lottery Ticket Grabbing My Attention

GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30%. Small research trial s more_horizontal

Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?

By Zacks Investment Research
December 2, 2022

Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?

Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year. more_horizontal

GlycoMimetics Could Surge If Q1 Data Readout Is Positive

By Seeking Alpha
November 11, 2022

GlycoMimetics Could Surge If Q1 Data Readout Is Positive

GlycoMimetics stock price jumped on November 9. Good cancer survival results may have lengthened the timeline for a trial readout. more_horizontal


Search within

Pages Search Results: